Redhill Biopharma (RDHL)

Earnings in 2023 (TTM): €6.97 Million

According to Redhill Biopharma's latest financial reports the company's current earnings are €35.74 Million. In 2022 the company made an earning of -€68.88 Million, an increase over its 2021 earnings that were of -€93.94 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Redhill Biopharma from 2012 to 2023

Annual earnings

Year	Earnings	Change
2023 (TTM)	€6.97 M	-110.13%
2022	-€68.88 Million	-26.68%
2021	-€93.94 Million	28.32%
2020	-€73.21 Million	80.06%
2019	-€40.66 Million	8.97%
2018	-€37.31 Million	-14.76%
2017	-€43.77 Million	55.07%
2016	-€28.23 Million	39.26%
2015	-€20.27 Million	96.9%
2014	-€10.3 Million	0.78%
2013	-€10.22 Million	16.93%
2012	-€8.74 Million

Earnings for similar companies or competitors

Company	Earnings	Earnings differencediff.	Country
Sanofi SNY	€7.11 B	63,915.21%	🇫🇷 France
Merck MRK	€14.38 B	129,289.91%	🇺🇸 USA
GlaxoSmithKline GSK	€4.00 B	35,942.78%	🇬🇧 UK
Taro Pharmaceutical TARO	€42.02 M	277.87%	🇮🇱 Israel
Teva Pharmaceutical Industries TEVA	€0.40 B	3,529.45%	🇮🇱 Israel

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Earnings for Redhill Biopharma (RDHL)

Earnings in 2023 (TTM): €6.97 Million